Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Columbia University
- Enrollment
- 416
- Locations
- 1
- Primary Endpoint
- Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)
Study Overview
Brief Summary
There are a growing number of adolescents with chronic medical conditions in the United States. The Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination and annual influenza vaccination of all adolescents. Pneumococcal polysaccharide vaccination is also recommended for certain high-risk patients. Limited studies suggest that vaccination coverage of this population remains sub-optimal. Text message vaccine reminder/recall has been shown to be effective in increasing uptake of select pediatric and adolescents vaccines, but has yet to be examined among patients with chronic medical conditions who may also face unique barriers to vaccination. This intervention aims to implement and evaluate the use of text message vaccine reminders among urban low-income minority adolescents with chronic medical conditions. This investigator-initiated study is supported in part by a grant from the Pfizer Medical Education Group.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Health Services Research
- Masking
- Triple (Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 11 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Parent with
- •adolescent aged 11-17 years;
- •adolescent with ≥1 chronic medical condition;
- •adolescent with clinic visit in last 12 months;
- •cell phone number listed in hospital registration system
Exclusion Criteria
- •Parent who:
- •does not speak English or Spanish;
- •is unwilling to receive text message vaccine reminders;
- •anticipates moving from area in coming 12 months
Outcomes
Primary Outcomes
Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)
Time Frame: 12 weeks after intervention start
Secondary Outcomes
- Percentage of eligible subjects with missed opportunities for HPV1, influenza, and/or pneumococcal vaccination(24 weeks after intervention start)
- Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)(24 weeks after intervention start)
Investigators
Annika Hofstetter
Assistant Professor of Pediatrics
Columbia University